Interpace Biosciences, Inc.
Interpace Biosciences, Inc., a leading player in the biotechnology sector, is headquartered in the United States, with significant operations across various regions. Founded in 2008, the company has established itself as a pioneer in molecular diagnostics and personalised medicine, focusing on innovative solutions for cancer detection and management. Interpace offers a range of unique products and services, including its proprietary tests that aid in the diagnosis and treatment of thyroid and other cancers. These offerings are distinguished by their ability to provide actionable insights, enhancing patient care and clinical decision-making. With a strong market position, Interpace has achieved notable milestones, including partnerships with healthcare providers and advancements in genomic testing technologies, solidifying its reputation as a trusted resource in the evolving landscape of precision medicine.
DitchCarbon Score
How does Interpace Biosciences, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Business Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Interpace Biosciences, Inc.'s score of 23 is lower than 79% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Interpace Biosciences, Inc.'s reported carbon emissions
Interpace Biosciences, Inc., headquartered in the US, currently does not have available data on carbon emissions, as no specific emissions figures have been reported. Additionally, there are no documented reduction targets or climate pledges outlined by the company. In the absence of concrete emissions data, it is essential to note that many companies in the biotechnology sector are increasingly focusing on sustainability and climate commitments. Interpace Biosciences may be engaging in similar initiatives, although specific details are not provided. As the industry evolves, stakeholders are encouraged to monitor the company's future commitments and actions regarding carbon emissions and climate impact.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Interpace Biosciences, Inc. is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
